Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about CADL, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Aglatimagene Besadenovec (CAN-2409) | Non-squamous, Non-Small Cell Lung Cancer | Phase 3 · NCT07660094 | Recruiting |
| Cytotoxic Chemotherapeutic Agent | Non Small Cell Lung Cancer | Phase 2 · NCT04495153 | Active not recruiting |
| Oncolytic HSV-1 rQNestin34.5v.2 | Malignant Glioma of Brain | Phase 1 · NCT03152318 | Active not recruiting |
Also used in these trials (approved or third-party drugs, not CADL's own candidates): Docetaxel Anhydrous, Pembrolizumab, Valacyclovir, Temozolomide, Cyclophosphamide, Nivolumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
CADL holds $203.1M in cash and short-term investments (as of Sep 30, 2026) and burns about $20.2M/quarter from operations, an estimated runway of 30.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 34 · Moderate
We believe our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements into the second quarter of 2028.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CADL files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| FMR, LLC | Institution (13F) | 11,570,386 | 14.75% | 2026-09-30 |
| Paul B Manning Director · +55,246 options |
Insider | 5,748,279 | 7.33% | 2026-02-23 |
| BlackRock, Inc. | Institution (13G, 5%+) | 4,834,899 | 6.16% | 2026-06-30 |
| State Street Corporation | Institution (13F) | 3,807,103 | 4.85% | 2026-09-30 |
| Portolan Capital Management, LLC | Institution (13F) | 3,538,561 | 4.51% | 2026-09-30 |
| Acorn Capital Advisors, LLC | Institution (13F) | 3,497,948 | 4.46% | 2026-09-30 |
| Saturn V Capital Management LP | Institution (13F) | 3,476,206 | 4.43% | 2026-09-30 |
| RTW Investments LP | Institution (13F) | 3,211,008 | 4.09% | 2026-09-30 |
| Vanguard Capital Management LLC | Institution (13F) | 2,947,019 | 3.76% | 2026-09-30 |
| Geode Capital Management, LLC | Institution (13F) | 1,705,887 | 2.17% | 2026-09-30 |
| Christopher Martell Director · +46,240 options |
Insider | 546,863 | 0.70% | 2025-06-25 |
| Paul Peter Tak Chief Executive Officer, Director · +2.79M options |
Insider | 113,321 | 0.14% | 2026-09-10 |
Share count 78,445,937 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-11-03 filed 2026-11-05 |
Ostrovsky Maria |
Option award (A) | 315,000 | – | – |
| 2026-09-30 filed 2026-10-02 |
PAPA JOSEPH C |
Option award (A) | 1,325 | $8.68 | – |
| 2026-09-30 filed 2026-10-02 |
Manning Paul B |
Option award (A) | 2,189 | $8.68 | – |
| 2026-09-30 filed 2026-10-02 |
Loggia Nicoletta |
Option award (A) | 380 | $8.68 | – |
| 2026-09-11 filed 2026-09-11 |
Tak Paul Peter |
Sale (S) | 59,379 | $10.46 | 113,321 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CADL and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →